Repoxygen

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Repoxygen was the tradename for a type of gene therapy to produce erythropoietin (EPO). It was under preclinical development by Oxford Biomedica as a possible treatment for anaemia but was abandoned in 2003. The project became infamous when it was mentioned during the criminal trial of Thomas Springstein, a former track coach for some German athletes, who was found guilty of giving athletes performance enhancing drugs without their knowledge. An email in which Springstein attempted to obtain Repoxygen was read by a prosecutor, which led to a flurry of media coverage. The World Anti-Doping Agency banned "gene doping" in 2003 and as of 2009 was researching detection methods for substances such as repoxygen.

Repoxygen was the tradename for a type of gene therapy to produce erythropoietin (EPO). It was under preclinical development by Oxford Biomedica as a possible treatment for anaemia but was abandoned in 2003. The project became infamous when it was mentioned during the criminal trial of Thomas Springstein, a former track coach for some German athletes, who was found guilty of giving athletes performance enhancing drugs without their knowledge. An email in which Springstein attempted to obtain Repoxygen was read by a prosecutor, which led to a flurry of media coverage. The World Anti-Doping Agency banned "gene doping" in 2003 and as of 2009 was researching detection methods for substances such as repoxygen.

Further reading

Patrick Barry. Aug. 2, 2008 Finding the Golden Genes. Science News 174(3):16-21 Yoshimi M, Maeyama T, Yamada M, Hamada N, Fukumoto J, Kawaguchi T, Kuwano K, & Nakanishi Y. (2008). Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Respirology 13(5). 639-645. Percy MJ. (2008). Familial erythrocytosis arising from a gain-of-function mutation in the HIF2A gene of the oxygen sensing pathway. Ulster Medical Journal 77(2). 86-88.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377216130 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.